What is HC Wainwright’s Estimate for DNLI FY2027 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities research analysts at HC Wainwright increased their FY2027 earnings per share estimates for shares of Denali Therapeutics in a report issued on Thursday, March 26th. HC Wainwright analyst A. Fein now expects that the company will earn ($1.41) per share for the year, up from their previous estimate of ($1.52). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2028 earnings at ($0.18) EPS, FY2029 earnings at $0.97 EPS and FY2030 earnings at $2.44 EPS.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same period in the previous year, the business posted ($0.67) earnings per share.

A number of other brokerages have also recently commented on DNLI. UBS Group began coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating on the stock. Morgan Stanley boosted their target price on shares of Denali Therapeutics from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. BTIG Research raised their price target on Denali Therapeutics from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Finally, The Goldman Sachs Group lifted their price target on Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.82.

Denali Therapeutics Price Performance

DNLI opened at $19.20 on Monday. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -6.46 and a beta of 1.02. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $20.47 and a 200-day moving average price of $17.93. Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $23.77.

Insider Buying and Selling at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the sale, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. This represents a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 12.50% of the company’s stock.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Denali Therapeutics by 8.9% during the fourth quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after purchasing an additional 1,064,972 shares in the last quarter. Baillie Gifford & Co. raised its stake in Denali Therapeutics by 6.2% in the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after purchasing an additional 719,304 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Denali Therapeutics by 28.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after purchasing an additional 1,615,565 shares in the last quarter. Temasek Holdings Private Ltd lifted its position in Denali Therapeutics by 30.9% during the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after purchasing an additional 1,657,142 shares during the last quarter. Finally, State Street Corp lifted its position in Denali Therapeutics by 14.6% during the fourth quarter. State Street Corp now owns 6,263,371 shares of the company’s stock valued at $103,408,000 after purchasing an additional 799,110 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.